PredictCan Biotechnologies is a startup driven by the willingness to advance and to improve precision medicine in oncology. Because cancer is a complex and heterogeneous disease that leads to major public health and economic issues worldwide, we believe that accurate and sensitive solutions are urgently needed to support patients and save lives.

At PredictCan Biotechnologies, we employ our long-lasting expertise in translational research and precision medicine to deliver innovative tools for cancer detection and treatment. We are continually reevaluating and adapting our products to medical inquiries to provide cutting-edge technologies to patients, clinicians, and pharmaceutical industries supporting their combat against cancer.

We envision a future in which our company as a companion of the health system, brings a personalized care solution to each patient increasing their likelihood to be cured.

Our Team


Hong Tuan DUONG, PhD

Chief Executive Officer

Dr. Hong Tuan DUONG is a cofounder of PredictCan Biotechnologies. He received his PhD in Pharmacology and Cell Biology from the University of Strasbourg and worked for eighteen years at the University of Basel in Switzerland developing and supervising experimental medicine research projects on innate immunity and liver diseases. He obtained his HDR/PD in experimental medicine from the Faculty of Medicine of Basel. Lately, he brought his expertise to the INSERM unit at the University of Strasbourg pursuing his efforts in precision oncology.



Chief Technical Officer

Dr. Sara CHERRADI is a cofounder of PredictCan Biotechnologies. She received her PhD in Cancer Biology from the University of Montpellier and completed a postdoctoral fellowship at the University of Strasbourg where she developed as a R&D leader solid expertise on patient-derived models for anticancer preclinical drug development and precision medicine.


Salomé ROUX

Research engineer

Salomé Roux obtained her engineer degree in applied biology from the Polytech school of Clermont-Ferrand (FRANCE). She worked for 4 years at the CNRS_UMR5203 in Montpellier in partnership with the biotech Revvity, where she acquired solid technical expertise in pharmacology, cellular, and molecular biology.

Advisory Board

Jean-François DUFOUR, MD PhD

Professor Jean-Francois Dufour received his degree in mathematics and MD degree from the University of Geneva, Switzerland. After training in internal medicine in Switzerland, he joined the laboratory of Professor I. Arias at Tufts University in Boston. He returned to the clinic to complete a gastroenterology fellowship with Professor M. Kaplan at the New England Medical Center. Then, Professor Dufour established his own laboratory at the University of Bern, Switzerland, where he was clinic director and head for Hepatology for 10 years.Professor Dufour is a member of the American Association for the Study of Liver Disease (fellow), the American Gastroenterology Association (fellow), the European Association for the Study of the Liver (EASL). He is a founding member of the International Liver Cancer Association. He was twice member of governing board of EASL as scientific committee member and then as educational councillor. He was member of the United European Gastroenterology educational committee. Professor Dufour has a large clinical experience and a broad understanding of basic and translational research, its bottleneck and the challenges in disseminating and exploiting knowledge. Professor Dufour has served as principal investigator on numerous clinical studies, focusing on NASH and hepatocellular carcinoma.

 He is an associate editor of GUT, and was an associate editor of Hepatology (writing the monthly ‘Highlights’ section), Journal of Hepatology and Liver International. Professor Dufour published more than 350 scientific publications. He is president of the Swiss Foundation against Liver Cancer as well as president of the Swiss NASH Foundation.

our partnerships

PredictCan Biotechnologies has built strong alliances with leading medical institutions that provides access to expertise and foster a collaborative environment where breakthroughs are made. Through synergetic efforts and shared vision, Predictcan Biotechnologies and its partners are driving forward the frontiers of precision and personalized medicine to bring the optimal treatment for each patient.